《生命科学》 2022, 34(11): 1336-1341

日本血凝病毒包膜的抗肿瘤应用策略研究进展

张佳琪¹ , 林华庆^1,* , 彭　程¹ , 刘寒冰¹ , 李晓冬²

¹广东药科大学/广东省药物新剂型重点实验室，广州 510000 ²杜邦中国集团上海分公司，上海 200000

摘　要：

日本血凝病毒包膜(HVJ-E) 可以通过增强肿瘤免疫反应、诱导肿瘤细胞凋亡以及靶向药物输送以达到高效治疗癌症的目的。诸多研究表明，HVJ-E 的免疫治疗联合化疗( 如与DTIC 联用)、放疗( 如与BNCT 联用)、热疗( 如将MNPs 与HVJ-E 结合) 等能够展现出协同抗肿瘤作用。但是，由于HVJ-E 全身给药易出现血凝问题，HVJ-E 的应用受到限制。近年研究发现，通过LbL 技术对其表面进行修饰，可以降低HVJ-E 的血凝问题，并增加对肿瘤的特异性。该文将简述HVJ-E 在肿瘤治疗上的应用策略，为促进HVJ-E 在肿瘤治疗领域的进一步开发提供参考。

通讯作者：林华庆 , Email:prof_huaqing@126.com

Advances in antitumor application strategy of hemagglutinating virus of Japan envelope

ZHANG Jia-Qi¹ , LIN Hua-Qing^1,* , PENG Cheng¹ , LIU Han-Bing¹ , LI Xiao-Dong²

¹Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems, Guangdong Pharmaceutical University, Guangzhou 510000, China ²Shanghai Branch, Du Pont China Holding Co., Ltd., Shanghai 200000, China

Abstract:

Hemagglutinating virus of Japan envelope (HVJ-E) can effectively cure cancer by enhancing tumor immune response, inducing tumor cell apoptosis, and targeted drug delivery. Numerous studies have proved that immunotherapy with HVJ-E combined with chemotherapy (e.g., in combination with DTIC), radiotherapy (e.g., in combination with BNCT), and thermotherapy (e.g., combining MNPs with HVJ-E) can demonstrate synergistic antitumor effects. However, due to its hemagglutination issues in systemic administration, the application of HVJ-E is limited. Recent studies have revealed that modification of its surface by LbL technology can reduce the hemagglutination problem of HVJ-E and increase the specificity to tumors. A brief review of the application strategy of HVJ-E in oncology therapy will be presented in this paper, aiming to provide a reference for the promotion of the further development of HVJ-E in the field of oncology therapy.

Communication Author：LIN Hua-Qing , Email:prof_huaqing@126.com